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ABSTRACT
Introduction: Influenza vaccination in pregnancy
is recommended for all women in Australia,
particularly those who will be in their second or third
trimester during the influenza season. However, there
has been no systematic monitoring of influenza
vaccine uptake among pregnant women in Australia.
Evidence is emerging of benefit to the infant with
respect to preventing influenza infection in the first
6 months of life. The FluMum study aims to
systematically monitor influenza vaccine uptake during
pregnancy in Australia and determine the effectiveness
of maternal vaccination in preventing laboratory-
confirmed influenza in their offspring up to
6 months of age.
Methods and analysis: A prospective cohort study
of 10 106 mother–infant pairs recruited between
38 weeks gestation and 55 days postdelivery in six
Australian capital cities. Detailed maternal and infant
information is collected at enrolment, including
influenza illness and vaccination history with a follow-
up data collection time point at infant age 6 months.
The primary outcome is laboratory-confirmed
influenza in the infant. Case ascertainment occurs
through searches of Australian notifiable diseases data
sets once the infant turns 6 months of age (with
parental consent). The primary analysis involves
calculating vaccine effectiveness against laboratory-
confirmed influenza by comparing the incidence of
influenza in infants of vaccinated mothers to the
incidence in infants of unvaccinated mothers.
Secondary analyses include annual and pooled
estimates of the proportion of mothers vaccinated
during pregnancy, the effectiveness of maternal
vaccination in preventing hospitalisation for acute
respiratory illness and modelling to assess the
determinants of vaccination.
Ethics and dissemination: The study was approved
by all institutional Human Research Ethics Committees
responsible for participating sites. Study findings will
be published in peer review journals and presented at
national and international conferences.
Trial registration number: The study is registered
with the Australia and New Zealand Clinical Trials
Registry (ANZCTR) number: 12612000175875.
INTRODUCTION
Influenza infection during pregnancy and in
the first 6 months of life is a substantial cause
of morbidity. During pregnancy, reported
cumulative incidence ranges from 4% to
22% in non-pandemic periods,1–4 and preg-
nant women are at an increased risk of
severe disease and death,4–7 particularly
during pandemic periods.8–10
Consequences for the fetus of influenza
infection during pregnancy are not well
established.11 An investigation of a cluster of
12 fetal deaths that occurred within 3 weeks
Strengths and limitations of this study
▪ The national approach, including women giving
birth in six capital cities in Australia will provide
broadly representative data on women and their
infants.
▪ The large sample size, over 10 000 mother–
infant pairs, with recruitment spread over four
influenza seasons will provide sufficient power to
detect a vaccine effectiveness of at least 40%
against laboratory-confirmed influenza in infants.
▪ The primary outcome, laboratory-confirmed influ-
enza in the infant is objective and is accessed
from national notifiable diseases data sets.
▪ Ascertainment bias for the primary outcome of
laboratory-confirmed influenza is likely to be
minimal and non-differential.
▪ Loss to follow-up will occur if the mother with-
draws from the study but will not affect ascer-
tainment of the primary outcome.
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during the influenza season in the UK found the case
pregnancies had an excess of recent flu-like illness, and
were more likely than controls to have serological evi-
dence of influenza A infection.12 Observational studies
have suggested maternal influenza infection during
pregnancy may increase the risk of mental health ill-
nesses in the offspring,13 14 although the evidence is
weak and predominantly limited to animal models.
The impact of influenza infection during infancy, par-
ticularly in the very young with high-risk conditions, can be
substantial, with higher hospitalisation rates than older chil-
dren and increased likelihood of intensive care admission
and respiratory failure.15 16 Influenza infection in infants
can also increase the risk of serious secondary invasive bac-
terial infections, particularly Streptococcus pneumoniae.17
Given the impact of influenza in pregnancy, maternal
influenza vaccination during pregnancy is now recom-
mended in many countries.18 19 Pregnant women are not
only considered a priority group for vaccination during
influenza pandemics, they are also identified by the
WHO as the priority for funded influenza vaccination
programmes globally (reference SAGE report). Influenza
vaccination during pregnancy is considered safe20 21 and
there is some evidence that it may also decrease the likeli-
hood of a baby being born premature or small for gesta-
tional age.22 Importantly, in recent years, data have
emerged indicating maternal influenza vaccination
during pregnancy may provide protection against influ-
enza infection in their infants up to 6 months of age,23–26
a group for whom there are currently no licensed vac-
cines. Given the varying nature of study designs and rela-
tively small sample sizes, larger studies are needed in a
variety of populations to confirm these findings.
Uptake of vaccine during pregnancy is not systematic-
ally monitored and studies suggest uptake is suboptimal
in many settings11 27–29 and there are few large studies
that have examined the reasons why. A woman’s percep-
tion of the benefits and risks of vaccine and whether or
not their health service provider recommended and/or
offered the vaccine appear to be key determinants.29–31
Large-scale prospective studies are required to monitor
seasonal vaccine uptake and its determinants during
pregnancy over time. Similarly, such studies are needed
to also improve the evidence for the effectiveness of
influenza vaccination during pregnancy in preventing
influenza in young infants. We present the study proto-
col for a national prospective cohort study of Australian
mother–infant pairs that aims to: (A) determine the
effectiveness of influenza vaccine in pregnancy in pre-
venting laboratory-confirmed influenza among infant
offspring up to 6 months of age, and (B) monitor influ-
enza vaccine uptake and its determinants over time.
METHODS AND ANALYSIS
Study design
FluMum is a 5-year prospective cohort study of 10 106
mother–infant pairs recruited between 38 weeks
gestation and 55 days postdelivery in six sites across
Australia over a 4-year period. The six study centres are
each affiliated with local public maternity units that col-
lectively average over 20 000 births/year. Primary end-
points are determined when the infant reaches
6 months of age. Recruitment is equal in all sites and is
scheduled to be completed by 25 October 2015 for
infants born up until 31 August (ie, within a 55-day post-
delivery window period). The follow-up period of obser-
vation for the last enrolled mother–infant pair is
scheduled to end on or before 31 March 2016.
Our primary objective is to assess the effectiveness of
influenza vaccine during pregnancy against laboratory-
confirmed influenza among infant offspring during the
first 6 months of life. Our secondary objectives are to:
A. Determine influenza vaccine uptake during preg-
nancy at each of six sentinel research centres during
each of four consecutive years.
B. Assess independent predictors of influenza vaccin-
ation in pregnancy, including: demographic factors;
obstetric history; knowledge and attitudes surround-
ing influenza and influenza vaccine and access to
influenza vaccination.
C. Determine the incidence of laboratory-confirmed
influenza infection during pregnancy.
D. Estimate the effectiveness of maternal influenza
vaccine in pregnancy against laboratory-confirmed
influenza in the mother during pregnancy, and hos-
pitalisation of the infant with acute lower respiratory
infection during the first 6 months of life.
Study sample
Eligible participants are identified from maternity units
and primary healthcare settings in the six cities.
Participants are approached by study personnel who
explain the study and obtain informed consent.
Women are eligible for the study if they are aged
17 years or more at the time of consent, are at least
38 weeks gestation or have delivered a live born infant
who is no older than 55 days at enrolment and if the
participant (mother) has sufficient verbal English to
permit questionnaire completion at study entry and at
the 6-month follow-up. For the purposes of the primary
analysis, women are excluded from the study if they are
(A) planning to move overseas before the infant reaches
6 months of age, or (B) have received influenza vaccin-
ation less than 14 days prior to delivery. Those partici-
pants who enrol but subsequently are lost to follow-up at
age 6 months remain eligible for assessment of the sec-
ondary outcomes at the time of enrolment.
Once consent is obtained, an interviewer-administered
questionnaire is completed that collects detailed infor-
mation on maternal self-reported influenza and pertussis
vaccination status, information relating to the barriers/
influences of influenza and pertussis vaccination,
contact details for the participant’s usual medical practi-
tioner, self-reported maternal medical/obstetric history
and some sociodemographic indicators. An additional
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telephone and/or email contact occurs once the infant
reaches 6 months of age to seek parent-reported epi-
sodes of medically diagnosed influenza in the infant.
Outcomes to be measured
In Australia, influenza is a nationally notifiable disease
with local notification requirements according to state
public health laws. The uniform notification case defin-
ition requires laboratory confirmation. Hence, for our
outcomes of laboratory-diagnosed influenza in the
infant or in the mother from 12 months prior to deliv-
ery to 6 months postdelivery, individual data are
obtained with consent from state/territory administered
data sets of laboratory-confirmed influenza results. We
match all notifications of episodes of laboratory-
confirmed influenza and/or any other vaccine prevent-
able diseases recorded by the notifiable diseases systems
within each state/territory for infant (6 months postde-
livery) and maternal influenza. Participant-reported epi-
sodes of medically diagnosed influenza where a
specimen was collected from the mother or the infant
but not notified will be followed up with the treating
physician to establish if they were laboratory confirmed
and had not been notified to the relevant public health
authority.
Our secondary outcome of vaccine uptake in preg-
nancy requires a valid date of vaccination for a partici-
pant to be considered vaccinated. Each participant’s
usual medical practitioner/vaccine provider will be con-
tacted to confirm the date of vaccination when a partici-
pant self-reports receipt of influenza vaccination but is
unable to cite the date given from a written record, or
where the participant is unsure of her vaccination history.
Participants who state that they have not been vaccinated
are considered unvaccinated.
Sample size and analysis plan
Accounting for a potential loss to follow-up of 10%, the
sample size calculation requires 10 106 women to be
recruited over the 4-year recruitment period. There will
be power of 80% (α=0.05) to detect vaccine effectiveness
against laboratory-confirmed influenza in infancy of at
least 40% assuming cumulative incidence among the
unvaccinated cohort of 2.3% for laboratory-confirmed
influenza in infants up to 6 months of age and average
vaccine uptake in pregnancy of 30%, both calculated
over the 4-year study period. Disease incidence and
vaccine uptake are averaged over the 4-year study period
as fluctuations are expected.
Estimates of vaccine uptake per year per site will be
accurate to within ±5% with the proposed sample size of
422 participants per year per site, for example: 15%
uptake (95% CI 11.9% to 18.7%); 25% uptake (95% CI
21.2% to 29.3%); 35% uptake (95% CI 30.6% to
39.5%); 45% uptake (95% CI 40.3% to 49.5%).
Similarly, the study is well powered to monitor a range of
predictors of influenza vaccination in pregnancy includ-
ing changes over time and differences between sites,
particularly so for the pooled data from over 10 000
participants.
The primary analysis will be a comparison of the cumu-
lative incidence of laboratory-confirmed influenza in
infants aged <6 months by treatment group (vaccinated
cohort vs unvaccinated cohort). VE Q8will be calculated as
(1−relative risk) × 100 and reported with 95% CIs. The
relative risk is approximated by the OR from logistic
regression. As noted previously, those women receiving
influenza vaccine less than 14 days prior to delivery will
be excluded in the primary analysis. A propensity score
approach will be used to account for differences in base-
line characteristics between groups.32 The propensity
score, defined as the conditional probability of receiving
the vaccine given the measured confounders,33 will be
estimated from a logistic regression model with receipt
of vaccine as the dependent variable and including all
variables considered to be potential confounders as
independent variables. Participants will be weighted by a
function of the propensity score in order to construct a
pseudo population in which there is no confounding by
observed variables. In particular, each mother–infant
pair who receives the vaccine is weighted by the inverse
of their estimated propensity score and each mother–
infant pair who does not receive the vaccine is weighted
by the inverse of 1 minus their propensity score. The
relative risk of influenza associated with the vaccine will
then be estimated using weighted logistic regression with
vaccination being the sole independent variable. In
2014, the protocol was amended (and approved by the
relevant ethics committees) to limit our analyses to the
first-born infant only in cases of multiple births.
Control for potentially important confounding factors
will be incorporated into the study. Consistent with previ-
ous studies, these will include maternal comorbidities,
maternal influenza infection during pregnancy and
potential influenza risk factors in infancy such as poten-
tial exposure to other individuals in the household,
attendance of older siblings in day care or primary
school, household smoking and breastfeeding. We will
also consider the sensitivity of the results to a number of
other potentially important factors that could be asso-
ciated with the risk of influenza in infancy including the
trimester of influenza vaccination, history of maternal
influenza vaccination in previous years, severity of the
influenza season, the infant’s month of birth, indigen-
ous status, gestational age and birth weight.
Maternal influenza infection during pregnancy will be
ascertained using standard surveillance definitions of
influenza-like illness derived from self-report and from
medical record review and adjusted by state/territory.
Assessment of the magnitude of the influenza infection
risk in infancy within each state/territory will be made.
This will be done through a comparison of influenza
incidence in the unvaccinated cohort against data on
the incidence of influenza among two slightly
older infant cohorts for the same period (infants aged
6–<12 months and those aged 12–<18 months). The
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disease burden in these two older cohorts will be
assumed to be similar to but not more than the
expected disease burden in the younger cohort since
this has been the pattern for some time (unpublished
data, NCIRS). Western Australia (WA) is the only state
that has an active infant influenza vaccination pro-
gramme starting from 6 months of age. Vaccine uptake
and disease incidence are already being carefully moni-
tored in WA with respect to their childhood influenza
vaccination programme.34
Secondary analyses will incorporate multivariate logis-
tic regression models to monitor changes in vaccine
uptake by site and year and to identify independent pre-
dictors of vaccine uptake during pregnancy by study site
and year. Subject to availability of outcome data, we have
planned interim analyses of the primary objective on an
annual basis using the pooled data to that point in time
but with α=0.001 so as not to adversely impact on the
overall power of the study. The purpose of the interim
analyses is to track annual progress towards demonstra-
tion of vaccine effectiveness over time. Potential benefits
to the infant from maternal influenza immunisation may
be highest in the first 3 months of life. We will therefore
also analyse the time to first episode of laboratory-
confirmed influenza infection in infants using survival
analyses methods.
DISCUSSION
Influenza infections during pregnancy and early infancy
are of global public health importance. Large
population-based studies that account for seasonal varia-
tions in influenza incidence are needed to monitor
public health recommendations and to determine the
effectiveness of the vaccine in preventing laboratory-
confirmed influenza. The FluMum study aims to address
this need through a national cohort study of over 10 000
mother–infant pairs conducted over four influenza
seasons.
The major strengths of our study are the national
approach, the sample size and that the primary outcome
can be determined through accessing information on
laboratory-confirmed notifications of influenza from
state/territory notifiable diseases data sets using individ-
ual consent obtained prior to occurrence of the
outcome of interest. Influenza is a notifiable disease in
Australia and that is a well-known requirement among
physicians and laboratories. We believe the simplicity of
the study design—incorporating recruitment at/near
delivery, ascertainment of infant exposure status at day 0
(delivery) then ascertainment of the primary outcome
from administrative data sets––will maximise maternal
participation rates, minimise drop out and thus minim-
ise the risk of response bias. Ascertainment bias for the
primary outcome of laboratory-confirmed influenza is
likely to be minimal and non-differential given that
maternal vaccination is: (A) unlikely to influence care-
seeking behaviour for severe respiratory illness in early
infancy; (B) unlikely to influence the healthcare provi-
der’s decision to submit a specimen for laboratory
testing and (C) would not influence the laboratory
undertaking the test since maternal vaccination history
would be unknown to the laboratory undertaking testing
of an infant’s specimen.
We are cognisant of the risk of potential bias between
the vaccinated and unvaccinated cohort and will
account for key differences in baseline characteristics as
mentioned previously. There is a risk that vaccinated
mothers may be more willing to participate than unvac-
cinated mothers; while a high response rate will help
mitigate this, we will also seek ethics approval to ask
mothers who do not consent if we can record a brief
reason why not, which will include the option that they
have not received an influenza vaccine. Given the study
is being conducted in urban centres, the generalisability
of the findings will be limited to women and infants in
those settings, although we will be able to determine
how many participants were from rural and remote
areas.
Loss to follow-up is a concern for any cohort study.
Women may choose to withdraw or there may be a failure
to contact them at the 6-month time period. This loss to
follow-up will not affect ascertainment of the primary
outcome (laboratory-confirmed influenza in the infant)
given the sources of that information are notifiable dis-
eases data sets, unless the infant has moved interstate or
overseas. If that does occur, the effect on the primary ana-
lysis is likely to be non-differential as discussed previously.
However, there are several strategies in place to minimise
attrition. Study operating procedures for follow-ups
include telephone, email and short message service (text
messaging), with a minimum of three attempts required.
Regular study newsletters are distributed to participants
to keep them informed of the study progress and to
remind them to contact study staff if their contact details
change. Our data linkage to notifiable diseases data sets
will still capture cases of laboratory-confirmed influenza
among those who are lost to follow-up, unless the partici-
pant has moved interstate or overseas. Sensitivity analyses
that account for missing data will be undertaken to deter-
mine the effect of loss to follow-up on our vaccine effect-
iveness estimates.
CONCLUSION
The FluMum study will be an important contribution to
maternal and infant child health policy and practice in
Australia, and potentially globally. Recruitment for the
study started in March 2012 and will cease in December
2015. While some Australian states are currently consid-
ering incorporating maternal vaccination during preg-
nancy into perinatal data collections, that is likely to be
some years away and hence the FluMum study will
provide information critical to improving and maintain-
ing influenza vaccine uptake in pregnancy. If we deter-
mine that influenza vaccination during pregnancy is
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effective in preventing laboratory-confirmed influenza in
infants, it will provide an additional incentive for women
to be vaccinated.
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